Cochrane · systematic review · CD006135
Probiotics for treating eczema
Makrgeorgou, A, Leonardi‐Bee, J, Bath‐Hextall, FJ, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 16.7%Low 4 · 66.7%Moderate 1 · 16.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: male and female patients 0 to 55 years of age with physician‐diagnosed eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome 1: participant‐ or parent‐rated symptoms of eczema (SCORAD part C) at the end of active treatment Visual analogue scale for itch and sleep disturbance ranging from 0 to 10 for each symptom and combined ranging from 0 to 20. The hig... | no estimate extracted | 13 studies · 754 participants | Moderate Downgraded: inconsistency |
Primary outcome 1: participant‐ or parent‐rated global change in eczema symptoms at the end of active treatment (binary outcome) Change in risk for worsened/unchanged eczema Duration of | OR 0.4 [0.14, 1.15] | 3 studies · 135 participants | Low Downgraded: imprecision, inconsistency |
Primary outcome 2: participant‐ or parent‐rated participant quality of life score at the end of active treatment Scales used: DLQI, IDQoL, Skindex‐29, CDLQI. On those scales, the higher the score, the more severely the quality of life is affected ... | no estimate extracted | 6 studies · 552 participants | Low Downgraded: imprecision, inconsistency |
Primary outcome 2: participant‐ or parent‐rated family quality of life score at the end of active treatment Scale used: DFI, FDLQI. On those scales, the higher the score, the more severely the quality of life is affected Duration of | no estimate extracted | 3 studies · 358 participants | Very low Downgraded: imprecision, inconsistency |
Secondary outcome 4: global eczema severity score (total SCORAD) at the end of active treatment (Investigator‐rated eczema severity) Scale used: total SCORAD ranging from 0 to 103. The higher the score, the more severe the disease Duration of | no estimate extracted | 24 studies · 1596 participants | Low Downgraded: imprecision, inconsistency |
Secondary outcome 6: adverse events (gastrointestinal symptoms) during active treatment Duration of | RR 1.54 [0.9, 2.63] | 7 studies · 402 participants | Low Downgraded: imprecision, inconsistency |